Analyst Price Targets — CGON
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 26, 2026 1:03 pm | — | UBS | $90.00 | $66.67 | TheFly | CG Oncology price target raised to $90 from $60 at UBS |
| February 10, 2026 2:19 pm | — | Truist Financial | $75.00 | $53.39 | TheFly | CG Oncology price target raised to $75 from $66 at Truist |
| January 21, 2026 11:34 am | — | RBC Capital | $73.00 | $54.69 | TheFly | CG Oncology price target raised to $73 from $61 at RBC Capital |
| January 16, 2026 11:55 am | Kelsey Goodwin | Piper Sandler | $70.00 | $53.07 | TheFly | CG Oncology price target raised to $70 from $55 at Piper Sandler |
| January 12, 2026 11:19 am | — | Goldman Sachs | $82.00 | $54.20 | TheFly | CG Oncology price target raised to $82 from $55 at Goldman Sachs |
| January 9, 2026 7:49 pm | — | Morgan Stanley | $93.00 | $54.20 | TheFly | CG Oncology price target raised to $93 from $89 at Morgan Stanley |
| January 9, 2026 7:47 pm | — | Truist Financial | $66.00 | $54.18 | TheFly | CG Oncology price target raised to $66 from $62 at Truist |
| January 8, 2026 12:39 pm | Sean Laaman | Morgan Stanley | $89.00 | $42.09 | TheFly | CG Oncology price target raised to $89 from $82 at Morgan Stanley |
| December 11, 2025 1:19 pm | — | Wedbush | $70.00 | $41.30 | TheFly | CG Oncology initiated with an Outperform at Wedbush |
| November 24, 2025 12:36 pm | Gregory Renza | Truist Financial | $62.00 | $42.44 | TheFly | CG Oncology initiated with a Buy at Truist |
Latest News for CGON
CG Oncology stock surges as early phase III data, strong bladder cancer results and a $900M cash cushion fuel rising investor confidence.
JPMorgan Chase and Co. boosted its stake in CG Oncology, Inc. (NASDAQ: CGON) by 321.3% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 227,879 shares of the company's stock after buying an additional 173,785 shares during the period. JPMorgan
Kynam Capital sold 1,059,375 shares of CG Oncology in the fourth quarter; the estimated trade size was $43.84 million based on quarterly average prices. Meanwhile, the quarter-end position value decreased by $41.50 million, reflecting both trading activity and price movement.
CG Oncology (NASDAQ: CGON - Get Free Report) is anticipated to announce its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($0.61) per share for the quarter. Investors can check the company's upcoming Q4 2025 earning summary page for the latest details on the call
ArrowMark Colorado Holdings LLC cut its position in CG Oncology, Inc. (NASDAQ: CGON) by 12.2% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 257,230 shares of the company's stock after selling 35,776 shares during the quarter. ArrowMark Colorado Holdings
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CGON.
U.S. House Trading
No House trades found for CGON.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.